Filana regains path to US epilepsy study for simufilam with $47m in cash

Filana Therapeutics has moved its simufilam epilepsy programme back toward the clinic. The US Food and Drug Administration released the hold on the company's investigational new drug application for seizures associated with tuberous sclerosis complex (TSC) in September. Filana disclosed the decision on 5 November alongside its third-quarter 2026 results.

The company is preparing a randomised, double-blind Phase 2a trial of about 40 patients at roughly 13 US sites, and expects screening to begin by the first quarter of 2027. The material reviewed gives no detail on dosing, endpoints or the reasons for the original hold, so the study's scientific design and the regulator's earlier concerns remain unclear.

The quarterly numbers frame the funding question. Filana reported $47.0m in cash and a net loss of $10.7m for the three months. It also reported a $31.25m escrow payment linked to a potential settlement of securities litigation. The material does not say how that payment relates to the cash balance or give other settlement terms, so it is not possible to say from these figures how far the money will stretch.

For context, an FDA clinical hold prevents a study from starting or continuing, and the agency releases it only once it is satisfied that the underlying concerns have been dealt with. Release of the hold therefore removes a regulatory barrier but does not by itself show that the trial will succeed.